Associate Professor of Medicine, Brigham and Women's Hospital
Cardiology
Dr. David A. Morrow, MD
|
|
Give Review
David A. Morrow, MD practices Cardiology. He studied medicine at Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1 in research and 12 in primary care medicine He has 3 awards "Regional Top Doctor", "Meaningful Use Stage 1 Certification" and "Fellow (FACC)". David Morrow is a published doctor and has 100 publications published. The lastest was: 'Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2P-TIMI 50).' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
- Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or...
- Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothromb...
- Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
- Prognostic Implications of Low Level Cardiac Troponin Elevation Using High-Sensitivity Cardiac Troponin T.
- New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo: Results From the TRA 2°P-TIMI 50 Trial.
- Coronary Stent Thrombosis With Vorapaxar Versus Placebo: Results From the TRA 2°P-TIMI 50 Trial.
- Effect of ranolazine on atrial fibrillation in patients with non-ST elevation Acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.
- Relation of T-Wave Alternans to Mortality and Nonsustained Ventricular Tachycardia in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome from the MERLIN-TI...
- ECG morphological variability in beat space for risk stratification after Acute coronary syndrome.
- Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease.
- Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease.
- Diagnostic Performance of Copeptin in Patients With Acute Nontraumatic Chest Pain: BWH-TIMI ED Chest Pain Study.
- Clinical Implications and Correlates of Q Waves in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolysis: Observations from the CLARITY-TIMI 28 Tr...
- Clinical Features, Use of Evidence-Based Therapies, and Cardiovascular Outcomes Among Patients With Chronic Kidney Disease Following Non-ST-Elevation Acute Coronary Sy...
- Erratum to: Evaluation of the diagnostic performance of Heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study.
- Real-world application of "delta" troponin: diagnostic and prognostic implications.
- Evaluation of the diagnostic performance of current and next-generation assays for cardiac troponin I in the BWH-TIMI ED Chest Pain Study.
- Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with Acute coronary syndromes in the ATLAS ACS-TIMI 46 trial.
- Vorapaxar in Patients With Peripheral Artery Disease: Results From TRA2{degrees}P-TIMI 50.
- Dynamic TIMI Risk Score for STEMI.
- Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
- Evaluation of the diagnostic performance of Heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study.
- Galectin-3 in cardiovascular Disease: a possible window into early myocardial fibrosis.
- Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with Acute coronary syndromes.
- Acute coronary syndromes: Reducing door-to-balloon time for STEMI-success at a price.
- Myocardial infarction accelerates atherosclerosis.
- Potassium concentration and repletion in patients with Acute myocardial infarction.
- ACC/AHA/ESC/WHF Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death: Observations from the TRITON-TIMI 38 Trial.
- Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients with Stable Coronary Disease.
- Delta Cardiac Troponin Values in Practice: Are We Ready to Move Absolutely Forward to Clinical Routine?
- Preamble: Impact of Biomarkers, Proteomics, and Genomics in Cardiovascular Disease.
- Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22.
- Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial.
- Prevention of cardiovascular Disease guided by total risk estimations - challenges and opportunities for practical implementation: highlights of a CardioVascular Clini...
- Myocardial Ischemia and Ventricular Tachycardia on Continuous Electrocardiographic Monitoring and Risk of Cardiovascular Outcomes After Non-ST-Segment Elevation Acute ...
- Central obesity and cardiovascular outcomes in patients with Acute coronary syndrome: observations from the MERLIN-TIMI 36 trial.
- Prognostic utility of secretory phospholipase A2 in patients with stable Coronary artery disease.
- Coronary flow reserve varies depending upon the location within the artery it is assessed and the TIMI myocardial perfusion grade: a PROTECT TIMI-30 analysis.
- Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an Acute coronary syndrome: Observations from the Pravastatin Or ...
- Highly Sensitive Troponin Assays and the Cardiology Community: A Love/Hate Relationship?
- Evaluation of NT-proBNP and High Sensitivity C-Reactive Protein for Predicting Cardiovascular Risk in Patients with Arthritis Taking Longterm Nonsteroidal Antiinflamma...
- Prognostic utility of neopterin and risk of heart failure hospitalization after an Acute coronary syndrome.
- Determining decision limits for new biomarkers: clinical and statistical considerations.
- Growth differentiation factor-15 and risk of recurrent events in patients stabilized after Acute coronary syndrome: observations from PROVE IT-TIMI 22.
- Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population.
- Antiplatelet therapy in Acute coronary syndrome (ACS): applying new science to clinical decisions.
- Novel biomarkers in cardiovascular Disease: update 2010.
- Relationship between nonsustained ventricular tachycardia after non-ST-elevation Acute coronary syndrome and sudden cardiac death: observations from the metabolic effi...
- Cardiovascular risk prediction in patients with stable and unstable Coronary heart disease.
- Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation Acute coronary syndrome.
- Being rational about (im)precision: a statement from the Biochemistry Subcommittee of the Joint European Society of Cardiology/American College of Cardiology Foundatio...
- Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation ...
- Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I.
- Clinical features and outcomes of women with unstable ischemic heart Disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevat...
- B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation Acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metab...
- Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation Myocardial infarction.
- Detection of myocardial injury in patients with unstable Angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial.
- Identification of genetic variants associated with response to statin therapy.
- Clinical application of sensitive troponin assays.
- Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.
- Economic impact of Angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial.
- Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural Myocardial infarction in the Trial to Assess Improvement in Therap...
- Efficacy of ranolazine in patients with chronic Angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranola...
- Ischemia detected on continuous electrocardiography after Acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less ...
- Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and Heart failure in patients with ST-elevation myocardial infarction in the TIMI ...
- Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation Myocardial infarction.
- Validation of an automated safety surveillance system with prospective, randomized trial data.
- Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after Acute co...
- Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation Myocardial infarction.
- Detection of Acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIM...
- Evaluation of high-sensitivity assays for cardiac troponin.
- Defining a role for novel biomarkers in Acute coronary syndromes.
- Outcomes of patients with Acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [...
- Biomarker release after percutaneous Coronary intervention: a message from the heart.
- The future of biomarkers in the management of patients with Acute coronary syndromes.
- Thrombus precursor protein and clinical outcomes in patients with Acute coronary syndromes.
- Antithrombotic therapy to support primary PCI.
- Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation Myocardial infarction.
- Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an Acute coronary syndrome in the Pravastatin or Atorvastatin Evaluati...
- Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with Acute coronary syndromes.
- Serial measurement of monocyte chemoattractant protein-1 after Acute coronary syndromes: results from the A to Z trial.
- Effect of ranolazine, an antiAnginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute ...
- Earlier detection of Myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity.
- Ranolazine in patients with Angina and coronary artery disease.
- Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysi...
- Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with Acute coronary syndrome.
- Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation Myocardial infarction.
- Appraisal of myeloperoxidase for evaluation of patients with suspected Acute coronary syndromes.
- Use of natriuretic peptides in clinical decision-making for patients with non-ST-elevation Acute coronary syndromes.
- Benchmarks for the assessment of novel cardiovascular biomarkers.
- Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous Coronary intervention in patien...
- Validating an automated outcomes surveillance application using data from a terminated randomized, controlled trial (OPUS [TIMI-16]).
- Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous Acute corona...
- Prognostic utility of heart-type fatty acid binding protein in patients with Acute coronary syndromes.
- Clinical relevance of C-reactive protein during follow-up of patients with Acute coronary syndromes in the Aggrastat-to-Zocor Trial.
- The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation Myocardial infarction: the ECG CLARITY-TIMI 28 Study.
- Association between blood glucose and long-term mortality in patients with Acute coronary syndromes in the OPUS-TIMI 16 trial.
- Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out.
Schools
Harvard Medical School
Brigham and Women39s Hospital
Procedures Preformed
- Ablation for Treatment of Cardiac Arrhythmias
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- View All
Conditions Treated
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Valve Disease
- Arrhythmias (incl. Atrial Fibrillation)
- View All
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Regional Top Doctor
- Meaningful Use Stage 1 Certification
- Fellow (FACC)
Education
-
Brigham and Women's Hospital -
Harvard Medical School
Hospital
-
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1316928039 | |
| NPPES Provider LastName | MORROW | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 021156110 | |
| NPPES Provider State | MA | |
| Specialty Description | Cardiology | |
| Total Claim Count | 348.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1316928039 |
| Last Name Of The Provider | MORROW |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Maros Ferencik, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer Lewey, MD |
|
|
Dr. Amit V. Khera, MD |
|
|
Dr. Tara K. Narula, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gaurav A. Upadhyay, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francine K. Welty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Randall M. Zusman, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Aarti Asnani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Haseeb Jafri, MD
This Doctor is OpenDoctor Recommended.
|